TR201903312T4 - Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. - Google Patents
Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. Download PDFInfo
- Publication number
- TR201903312T4 TR201903312T4 TR2019/03312T TR201903312T TR201903312T4 TR 201903312 T4 TR201903312 T4 TR 201903312T4 TR 2019/03312 T TR2019/03312 T TR 2019/03312T TR 201903312 T TR201903312 T TR 201903312T TR 201903312 T4 TR201903312 T4 TR 201903312T4
- Authority
- TR
- Turkey
- Prior art keywords
- benralizumab
- antigen
- binding fragment
- asthma
- weeks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Bathtubs, Showers, And Their Attachments (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864944P | 2013-08-12 | 2013-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201903312T4 true TR201903312T4 (tr) | 2019-04-22 |
Family
ID=52448837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/03312T TR201903312T4 (tr) | 2013-08-12 | 2014-08-07 | Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9441037B2 (enExample) |
| EP (1) | EP3033101B1 (enExample) |
| JP (4) | JP6746495B2 (enExample) |
| KR (2) | KR20220057637A (enExample) |
| CN (2) | CN111588848A (enExample) |
| AU (2) | AU2014306956B2 (enExample) |
| BR (1) | BR112016002401A8 (enExample) |
| CA (1) | CA2918105C (enExample) |
| CY (1) | CY1122132T1 (enExample) |
| DK (1) | DK3033101T3 (enExample) |
| ES (1) | ES2716906T3 (enExample) |
| HK (2) | HK1221644A1 (enExample) |
| HR (1) | HRP20190405T1 (enExample) |
| HU (1) | HUE042607T2 (enExample) |
| LT (1) | LT3033101T (enExample) |
| ME (1) | ME03348B (enExample) |
| MX (1) | MX368508B (enExample) |
| PL (1) | PL3033101T3 (enExample) |
| PT (1) | PT3033101T (enExample) |
| RS (1) | RS58404B1 (enExample) |
| RU (1) | RU2676333C2 (enExample) |
| SG (2) | SG11201600481UA (enExample) |
| SI (1) | SI3033101T1 (enExample) |
| SM (1) | SMT201900163T1 (enExample) |
| TR (1) | TR201903312T4 (enExample) |
| WO (1) | WO2015023504A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX368474B (es) * | 2013-08-12 | 2019-10-04 | Astrazeneca Ab | Uso de benralizumab para mejorar síntomas de asma. |
| HUE053627T2 (hu) * | 2013-08-12 | 2021-07-28 | Astrazeneca Ab | Módszerek a kényszerített kilégzési térfogat növelésére asztmásoknál benralizumab használatával |
| EP3057609A4 (en) * | 2013-10-15 | 2017-03-22 | Medlmmune, LLC | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| HRP20211371T1 (hr) * | 2013-10-24 | 2021-11-26 | Astrazeneca Ab | Stabilne, vodene formulacije protutijela |
| AU2015204674B2 (en) | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| US10699274B2 (en) | 2015-08-24 | 2020-06-30 | Samsung Electronics Co., Ltd. | Apparatus and method for secure electronic payment |
| US10846696B2 (en) | 2015-08-24 | 2020-11-24 | Samsung Electronics Co., Ltd. | Apparatus and method for trusted execution environment based secure payment transactions |
| CA3002761A1 (en) | 2015-11-04 | 2017-05-11 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
| US11542316B2 (en) | 2017-01-04 | 2023-01-03 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | S-Arrestin peptides and therapeutic uses thereof |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| TW202021983A (zh) * | 2018-09-21 | 2020-06-16 | 美商安納普提斯生物公司 | 用於嗜伊紅性氣喘之抗il-33療法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0811691B1 (en) | 1995-09-11 | 2004-12-01 | Kyowa Hakko Kogyo Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| EP1266663A4 (en) | 2000-02-15 | 2003-07-23 | Kyowa Hakko Kogyo Kk | INDUCER OF EOSINOPHILIC SPECIFIC APOPTOSIS |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| WO2005035583A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Ｉｌ－５受容体に特異的に結合する抗体組成物 |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| DK2068927T3 (da) | 2007-05-14 | 2016-01-18 | Medimmune Llc | Fremgangsmåder til reducering af eosinofilniveauer |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| MX2012005661A (es) * | 2009-11-18 | 2012-09-07 | Medicinova Inc | Tratamiento de exacerbacion aguda de asma y reduccion de probabilidad de hospitalizacion de pacientes que sufren de la misma. |
| RU2737245C2 (ru) * | 2010-12-16 | 2020-11-26 | Дженентек, Инк. | Способы диагностики и лечения, связанные с ингибированием тн2 |
| US8961965B2 (en) | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| KR20140097217A (ko) | 2011-11-01 | 2014-08-06 | 메디뮨 엘엘씨 | 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법 |
| HUE053627T2 (hu) * | 2013-08-12 | 2021-07-28 | Astrazeneca Ab | Módszerek a kényszerített kilégzési térfogat növelésére asztmásoknál benralizumab használatával |
| MX368474B (es) * | 2013-08-12 | 2019-10-04 | Astrazeneca Ab | Uso de benralizumab para mejorar síntomas de asma. |
-
2014
- 2014-08-07 HR HRP20190405TT patent/HRP20190405T1/hr unknown
- 2014-08-07 AU AU2014306956A patent/AU2014306956B2/en active Active
- 2014-08-07 HK HK16109784.3A patent/HK1221644A1/zh unknown
- 2014-08-07 KR KR1020227013308A patent/KR20220057637A/ko not_active Ceased
- 2014-08-07 WO PCT/US2014/050080 patent/WO2015023504A1/en not_active Ceased
- 2014-08-07 SG SG11201600481UA patent/SG11201600481UA/en unknown
- 2014-08-07 US US14/453,942 patent/US9441037B2/en active Active
- 2014-08-07 RU RU2016108723A patent/RU2676333C2/ru active
- 2014-08-07 CN CN202010449434.5A patent/CN111588848A/zh active Pending
- 2014-08-07 PL PL14835826T patent/PL3033101T3/pl unknown
- 2014-08-07 EP EP14835826.0A patent/EP3033101B1/en active Active
- 2014-08-07 MX MX2016001383A patent/MX368508B/es active IP Right Grant
- 2014-08-07 SI SI201431109T patent/SI3033101T1/sl unknown
- 2014-08-07 CA CA2918105A patent/CA2918105C/en active Active
- 2014-08-07 PT PT14835826T patent/PT3033101T/pt unknown
- 2014-08-07 BR BR112016002401A patent/BR112016002401A8/pt not_active Application Discontinuation
- 2014-08-07 KR KR1020167006559A patent/KR102390714B1/ko active Active
- 2014-08-07 JP JP2016534614A patent/JP6746495B2/ja active Active
- 2014-08-07 HK HK16113684.6A patent/HK1225302B/en unknown
- 2014-08-07 DK DK14835826.0T patent/DK3033101T3/en active
- 2014-08-07 LT LTEP14835826.0T patent/LT3033101T/lt unknown
- 2014-08-07 ES ES14835826T patent/ES2716906T3/es active Active
- 2014-08-07 SM SM20190163T patent/SMT201900163T1/it unknown
- 2014-08-07 RS RS20190305A patent/RS58404B1/sr unknown
- 2014-08-07 SG SG10202005560UA patent/SG10202005560UA/en unknown
- 2014-08-07 TR TR2019/03312T patent/TR201903312T4/tr unknown
- 2014-08-07 CN CN201480043448.XA patent/CN105451760A/zh active Pending
- 2014-08-07 ME MEP-2019-75A patent/ME03348B/me unknown
- 2014-08-07 HU HUE14835826A patent/HUE042607T2/hu unknown
-
2016
- 2016-09-02 US US15/255,508 patent/US20170198049A1/en not_active Abandoned
-
2019
- 2019-03-12 CY CY20191100294T patent/CY1122132T1/el unknown
-
2020
- 2020-02-24 AU AU2020201327A patent/AU2020201327A1/en not_active Abandoned
- 2020-04-03 JP JP2020067797A patent/JP2020128375A/ja not_active Withdrawn
-
2022
- 2022-06-07 JP JP2022092216A patent/JP2022120009A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108991A patent/JP2024129139A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201903312T4 (tr) | Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. | |
| HK1225302A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| CA2917603C (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| AU2020202564A1 (en) | Methods for improving asthma symptoms using benralizumab | |
| RU2840902C2 (ru) | Способы нормализации симптомов астмы с применением бенрализумаба | |
| HK40064505A (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40013807A (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40013807B (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40012636A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40012636B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK1225303B (en) | Methods for improving asthma symptoms using benralizumab | |
| HK1225300B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab |